New psoriasis drug faces Long-Term safety test
NCT ID NCT05739435
Summary
This study follows patients who have already tried the experimental drug ESK-001 in a previous trial. It aims to see how safe and effective the drug is when taken for a longer period of time to control plaque psoriasis. About 165 participants will continue taking one of two doses of ESK-001, with the option to stay on it until it becomes available by prescription.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigator SIte#1036
Overland Park, Kansas, 66210, United States
-
Investigator Site # 1006
San Antonio, Texas, 78213, United States
-
Investigator Site # 1011
Columbus, Indiana, 47201, United States
-
Investigator Site # 1012
Rapid City, South Dakota, 57702, United States
-
Investigator Site # 1013
Tampa, Florida, 33614, United States
-
Investigator Site # 1023
Rogers, Arkansas, 72758, United States
-
Investigator Site # 1029
Birmingham, Alabama, 35205, United States
-
Investigator Site # 1041
South Jordan, Utah, 84095, United States
-
Investigator Site # 2002
Waterloo, Ontario, N2J 1C4, Canada
-
Investigator Site # 2004
Mississauga, Ontario, L4Y 4C5, Canada
-
Investigator Site # 2007
North Bay, Ontario, PiB 3Z7, Canada
-
Investigator Site # 2008
Surrey, British Columbia, V3V 0C6, Canada
-
Investigator Site # 2010
Québec, Quebec, G1V 4X7, Canada
-
Investigator Site #1001
Phoenix, Arizona, 85032, United States
-
Investigator Site #1002
Sherman Oaks, California, 91403, United States
-
Investigator Site #1005
Rolling Meadows, Illinois, 60008, United States
-
Investigator Site #1007
Santa Monica, California, 90404, United States
-
Investigator Site #1010
Clarkston, Michigan, 48346, United States
-
Investigator Site #1015
Houston, Texas, 77056, United States
-
Investigator Site #1017
Owensboro, Kentucky, 42301, United States
-
Investigator Site #1018
Los Angeles, California, 90045, United States
-
Investigator Site #1019
Portland, Oregon, 97223, United States
-
Investigator Site #1021
Encinitas, California, 92024, United States
-
Investigator Site #1022
Philadelphia, Pennsylvania, 19103, United States
-
Investigator Site #1025
Hialeah, Florida, 33012, United States
-
Investigator Site #1026
Rockville, Maryland, 20850, United States
-
Investigator Site #1027
South Bend, Indiana, 46617, United States
-
Investigator Site #1031
New Brighton, Minnesota, 55112, United States
-
Investigator Site #1033
Norman, Oklahoma, 73071, United States
-
Investigator Site #1035
Macon, Georgia, 31217, United States
-
Investigator Site #1043
Sandy Springs, Georgia, 30328, United States
-
Investigator Site #2001
Edmonton, Alberta, T6G 1C3, Canada
-
Investigator Site #2003
Winnipeg, Manitoba, R3M 3Z4, Canada
-
Investigator Site #2005
Oakville, Ontario, L6J 7W5, Canada
-
Investigator Site #2006
London, Ontario, N6H 5L5, Canada
-
Investigator Site #2009
Toronto, Ontario, M3H 5Y8, Canada
-
Investigator site # 1028
Miami, Florida, 33175, United States
-
Investigator site # 1030
Fort Lauderdale, Florida, 33308, United States
Conditions
Explore the condition pages connected to this study.